IGI Logo

Gufic Biosciences is currently trading at Rs. 302.70, up by 6.25 points or 2.11% from its previous closing of Rs. 296.45 on the BSE.

The scrip opened at Rs. 307.00 and has touched a high and low of Rs. 318.30 and Rs. 291.25 respectively. So far 33306 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 339.55 on 04-Sep-2023 and a 52 week low of Rs. 177.10 on 29-Mar-2023.

Last one week high and low of the scrip stood at Rs. 318.30 and Rs. 291.25 respectively. The current market cap of the company is Rs. 2901.06 crore.

The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 1.86% and 23.14% respectively.

Gufic Biosciences (Gufic) has received approval from the Therapeutic Group Administration (TGA), Australia and the National Health Surveillance Agency (ANVISA), Brazil for Parecoxib Sodium 40mg Lyophilized Powder for Injection, a selective COX-2 inhibitor, which shall be used for short-term treatment of acute pain and post-operative pain in adult patients. 

Gufic has been persistently committed to saving and improving lives of patients across the globe with its continuous efforts through the international regulatory agencies to bring novel molecules for the mankind.

Gufic Biosciences is engaged in diversified business viz. Pharma, Healthcare, Bio- Technology, Seeds, Herbal etc.